Cargando…
Sirolimus-eluting coronary stents: a review
The sirolimus-eluting coronary stent received CE Mark approval in Europe in April 2002. In the US, FDA approval followed in April 2003. Since the preliminary results from the First-in-Man feasibility study were presented, several randomized, controlled trials have documented the profound antiprolife...
Autor principal: | Abizaid, Alexandre |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994032/ https://www.ncbi.nlm.nih.gov/pubmed/17580729 |
Ejemplares similares
-
Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007) -
Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023) -
Comparison of neointimal coverage between ultrathin biodegradable polymer‐coated sirolimus‐eluting stents and durable polymer‐coated everolimus‐eluting stents: 6 months optical coherence tomography follow‐up from the TAXCO study
por: Abhyankar, Atul, et al.
Publicado: (2020) -
Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022) -
A Randomized Controlled Trial Comparing BioMime Sirolimus-Eluting Stent With Everolimus-Eluting Stent: Two-Year Outcomes of the meriT-V Trial
por: Abizaid, Alexandre, et al.
Publicado: (2023)